medigraphic.com
ISSN 1561-3046 (Electronic)

2021, Number 2

<< Back Next >>

Rev Cub Med Mil 2021; 50 (2)

Smoking habit and comorbidity in patients with chronic obstructive pulmonary disease

Suárez RB, Bestard PLA, Cardosa GD, Rosell SA, Barrero VL

Language: Spanish
References: 17
Page:
PDF size: 287.08 Kb.


ABSTRACT

Introduction: Chronic obstructive pulmonary disease constitutes a health problem in Cuba and the world, its prognosis is related to several factors.
Objective: To characterize a series of hospitalized patients with chronic obstructive pulmonary disease, according to age, sex, phenotype, smoking habit and comorbid diseases.
Method: A descriptive cross-sectional study was carried out that included the 296 patients who were admitted to the Internal Medicine Service of the Central Military Hospital Dr. Carlos J. Finlay with the diagnosis of chronic obstructive pulmonary disease in the period of two years. Comorbid diseases were determined, the phenotype given by the clinical presentation of the patients (A, B, C and D); age, sex, smoking habit, time and amount of smoking. The Charlson comorbidity index was used to assess the associated comorbidity in COPD.
Results: 54 % of the patients were male, 96,9 % older than 50 years, 36,1 % phenotype C, and 76,6 % smokers. Hypertension was more frequent in phenotypes B, C and D, in more than 70 %, diabetes mellitus in 73,7 % of phenotype B, and ischemic heart disease in 61,7 % of phenotype D.
Conclusions: Most of the patients studied were male, older than 50 years, smokers for more than 10 years and phenotype C. The most frequent comorbid diseases were arterial hypertension, diabetes mellitus and ischemic heart disease.


REFERENCES

  1. OPS. Informe sobre Control de Tabaco para la Región de las Américas. Washington DC: OPS/OMS; 2016[acceso: 05/11/2020]. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/28380/9789275318867_spa.pdf

  2. Legrá AN, Toledano GPY, Riverón PI, Del Campo MM, Silvera DS. Caracterización clínico epidemiológica de pacientes con enfermedad pulmonar obstructiva crónica MEDISAN. 2014[acceso: 05/11/2020]; 18(9):1274. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192014000900013

  3. Iglesias Becoña E. Trastornos relacionados con sustancias y trastornos adictivos. C Med Psicosom. 2014[acceso: 05/11/2020];110: 58-61. Disponible en: https://dialnet.unirioja.es/descarga/articulo/4803011.pdf

  4. Benet M, Espinosa A, Morejón A, Diez E, Landrove O, Ordúñez P. La prevalencia de tabaquismo en la ciudad de Cienfuegos, Cuba. MEDICC Review. 2014[acceso: 05/11/2020]; 16(3-4): Disponible en https://mediccreview.medicc.org/articles/mr_481_es.pdf

  5. González J, Marín M, Sánchez-Salcedo P, Zulueta JJ. Lung cancer screening in patients with chronic obstructive pulmonary disease. Ann Transl Med. 2016[acceso: 05/11/2020]; 4(8):160. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860483/

  6. OPS. Informe sobre Control de Tabaco para la Región de las Américas. A los 10 años del convenio Marco de la Organización Mundial de la Salud para el control del tabaco. Washington DC: OPS/OMS; 2016[acceso: 05/11/2020]. Disponible en: http://iris.paho.org/xmlui/bitstream/handle/123456789/28380/9789275318867_spa.pdf

  7. Albiol Chiva J. EPOC y Tabaquismo. [Trabajo de fin de grado]. Madrid: Universidad Complutense; 2015[acceso: 05/11/2020]. Disponible en: https://eprints.ucm.es/47799/1/ALBIOL%20CHIVA%2C%20JAUME.pdf

  8. Noé DV, García GL, Sansores H, Ramírez VA. Impacto del tabaquismo y la EPOC sobre el funcionamiento cerebral. Neumol Cir Torax. 2014[acceso: 05/11/2020]; 73(3):196-204. Disponible en: http://www.medigraphic.com/pdfs/neumo/nt-2014/nt143h.pdf

  9. Burkhardt R, Pankow W. The Diagnosis of Chronic Obstructive Pulmonary Disease. Dtsch Arztebl Int. 2014[acceso: 05/11/2020]; 111(49):834-46. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284520/

  10. Hong Y, Lim MN, Kim WJ, Rhee CK, Yoo KH, Lee JH, et al. Influence of Environmental Exposures on Patients with Chronic Obstructive Pulmonary Disease in Korea. Tuberc Respir Dis (Seoul). 2014[acceso: 05/11/2020];76(5):226-32. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24920949/

  11. Fabbri LM. Smoking, not COPD, as the disease. N Engl J Med. 2016[acceso: 05/11/2020]; 374(19):1885-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27168438/

  12. Cortés DP, López SB. Tabaquismo pasivo en el hogar: una invitación a la reflexión. Rev Clín Med Fam. 2014[acceso: 05/11/2020]; 7(3):234-7. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-695X2014000300010

  13. Jiménez RCA, Solano RS, Signes CJ, De Higes ME, Granda OJI, Lorza BJJ, et al. Budgetary impact analysis on funding smoking cessation drugs in patients with COPD in Spain. Int J Chron Obstruct Pulmon Dis. 2015[acceso: 05/11/2020]; 10:2027-36. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590338/

  14. De la Iglesia Martínez F, Serrano Arreba J, Montes Santiago J. Enfermedad obstructiva crónica (EPOC) y comorbilidades. Galicia Clin. 2012[acceso: 05/11/2020]; 73(Supl.1):S30-S36. Disponible en: https://galiciaclinica.info/PDF/17/310.pdf

  15. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008[acceso: 05/11/2020]; 5(4):549-55. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645334/

  16. Regan EA, Lynch DA, Curran-Everett D, Curtis JL, Austin JHM, Grenier PA, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med. 2015[acceso: 05/11/2020]; 175(9):1539-49. Disponible en: http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2323415?

  17. Franssen FM, Soriano JB, Roche N, Bloomfield PH, Brusselle G, Fabbri LM, et al. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med. 2016[acceso: 05/11/2020];194(5):568-76. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27442601/




2020     |     www.medigraphic.com